RxDoctor Payments Data

David Ardaya

Optometrist · Whittier, CANPI 1356370712

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (39.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 65.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $2,054 and has fallen 67.5% since, to $668 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,157in general payments, 2019–2025

Across 71 payments — averaging $114.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$5K
  • Coopervision Inc.$2K
  • Johnson & Johnson Surgical Vision, Inc.$135
  • Optos, Inc.$112
  • Glaukos Corporation$75
  • Sight Sciences, Inc.$71
  • plus $119 from 4 others
$39,147in research payments, 2019–2025

Across 4 payments — averaging $9786.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Vision Care, Inc.$23K
  • Coopervision Inc.$16K

What the payments were for

  • Speaking & faculty fees$3,25040%
  • Travel & lodging$1,71621%
  • Food & beverage$3,07938%
  • Entertainment$1121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,157 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California →

Medicare billing

Part B allowed, 2024
$7,547
Medicare patients
41
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate14$1,741
Latanoprost315$1,721
Azelastine Hcl102$1,678
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$257
Timolol Maleate24$191
Dorzolamide Hcl13$136

Paid to pharmacies, not to this prescriber.

Other optometrist in Whittier

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →